GlassScriptPhysician profile
Stacy L Young
NPI 1942682984
$2,923.25
in general payments reported to CMS, 2019-2025
38 companies · $69.91 in 2025
The $69.91 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,608 · 2022: $307 · 2023: $534 · 2024: $404 · 2025: $69.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.46 | 2021 | |
| Abbvie INC. | $279.38 | 2021-2025 | |
| Amgen INC. | $254.95 | 2021-2023 | Otezla |
| Medtronic, INC. | $200.30 | 2022-2024 | Solitaire X, Corevalve Evolut R, Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $194.42 | 2021-2023 | Austedo |
| Biohaven Pharmaceuticals, INC. | $181.36 | 2021 | |
| Biogen, INC. | $170.06 | 2021-2022 | |
| Edwards Lifesciences Corporation | $132.85 | 2024 | Pascal |
| Janssen Pharmaceuticals, INC | $132.30 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $116.27 | 2024 | |
| Novartis Pharmaceuticals Corporation | $107.64 | 2021-2023 | |
| Emd Serono, INC. | $96.57 | 2021-2023 | Mavenclad |
| Allergan, INC. | $66.84 | 2021-2022 | |
| Genzyme Corporation | $57.13 | 2021 | |
| Banner Life Sciences, LLC | $52.98 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $50.80 | 2021-2023 | Vyepti |
| Lilly USA, LLC | $49.41 | 2021-2023 | Emgality, Reyvow |
| Acadia Pharmaceuticals INC | $46.69 | 2021-2023 | Nuplazid |
| Eisai INC. | $41.42 | 2021-2022 | |
| Sk Life Science, INC. | $41.35 | 2021 | |
| Pfizer INC. | $35.45 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $32.77 | 2021 | |
| Almatica Pharma LLC | $31.57 | 2021 | |
| Biodelivery Sciences International, INC. | $24.73 | 2021 | |
| Intercept Pharmaceuticals, INC. | $20.35 | 2025 | Ocaliva |
| Mdd US Operations, LLC | $20.29 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.70 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.09 | 2024 | Qelbree |
| Neurelis, INC. | $18.36 | 2021 | |
| Abbott Laboratories | $17.69 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.43 | 2022 | |
| Kyowa Kirin, INC. | $14.29 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.52 | 2021 | |
| Horizon Therapeutics Plc | $13.02 | 2021 | |
| Tanabe Pharma America, INC. | $12.82 | 2021 | |
| Adamas Pharmaceuticals, INC. | $12.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 | |
| Collegium Pharmaceutical, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.